CAMP and ovarian neoplasm: Neutralization of LL-37 in vivo, using an anti-LL-37 antibody, significantly reduced the engraftment of MSCs into ovarian tumor xenografts developed from OVCAR-3 ovarian cancer cells, resulting in inhibition of tumor growth as well as disruption of the fibrovascular network (Coffelt et al. 2009).